Calcium Gluconate: Nursing Drug Guide, Extravasation Risk & IV Safety
IV calcium gluconate replaces ionized calcium in acute symptomatic hypocalcemia—but extravasation can cause calcinosis and tissue necrosis, and a rapid bolus can trigger bradycardia or fatal arrhythmias, especially with digoxin on board. Dilute, infuse slowly with ECG monitoring, use a secure peripheral or central line, and never Y-site ceftriaxone with calcium.
Calcium Gluconate Injection can cause calcinosis cutis, tissue necrosis, and secondary infection with or without extravasation. Rapid IV administration may cause hypotension, bradycardia, arrhythmias, syncope, or cardiac arrest—dilute, infuse slowly, and monitor ECG. Concomitant ceftriaxone and IV calcium is contraindicated in neonates ≤28 days; in older patients, never administer simultaneously through a Y-site—flush lines between infusions. Hypercalcemia is a contraindication.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm hypocalcemia or a valid prescriber indication, verify the line is patent and not shared with ceftriaxone (absolute contraindication in neonates ≤28 days), dilute per label, and cap bolus rates at 200 mg/min in adults and 100 mg/min in pediatrics with continuous ECG monitoring. Stop the infusion immediately for extravasation, bradycardia, or new arrhythmia—and recheck ionized calcium within the label monitoring intervals.
Most common brand names
Calcium gluconate injection is supplied generically as Calcium Gluconate Injection, USP (100 mg calcium gluconate per mL). Manufacturer names on the vial (e.g., Fresenius Kabi, Hikma, B. Braun) reflect packaging—not different active ingredients.
Common presentations: 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials; 10,000 mg/100 mL pharmacy bulk package (not for direct infusion). Do not confuse with: calcium chloride injection—calcium chloride delivers substantially more elemental calcium per mL and has different extravasation toxicity.
Why we give it — Indications
FDA labeling limits the approved indication to acute symptomatic hypocalcemia in adults and pediatric patients. Nurses also encounter calcium gluconate in institutional emergency protocols (for example, cardiac membrane stabilization when hyperkalemia with ECG changes is present)—those doses follow local protocol and are outside the product indication unless your facility policy cites the order pathway.
| Use | Detail |
|---|---|
| Acute symptomatic hypocalcemia (labeled) | Replace ionized calcium when hypocalcemia causes neuromuscular or cardiovascular symptoms—often after parathyroid surgery, massive transfusion/citrate toxicity, hungry bone syndrome, or critical illness. Individualize dose to severity, serum calcium level, and acuity per Table 1 in prescribing information. |
| Institutional emergency use (protocol-driven) | Some services order IV calcium for hyperkalemia with ECG changes as a temporizing measure while definitive potassium-lowering therapy is prepared. Dosing for this use is not specified in the reviewed Calcium Gluconate Injection prescribing information—follow prescriber orders and local emergency protocol only. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Calcium gluconate is a soluble calcium salt. After IV administration it dissociates into ionized calcium—the biologically active fraction that stabilizes excitable membranes, supports cardiac contractility, and enables normal neuromuscular transmission. Hypocalcemia prolongs QT interval and lowers seizure threshold; replacement restores ionized calcium but must be titrated because overshoot causes hypercalcemia. Ionized calcium is the bedside-relevant lab; total calcium on a basic metabolic panel must be interpreted with albumin and pH. Hepatic metabolism does not alter availability after IV dosing per labeling.
Dosing overview
Each mL contains 100 mg calcium gluconate (9.3 mg [0.465 mEq] elemental calcium). Individualize within Table 1 ranges based on symptom severity, serum calcium, and acuity. Verify every calculation against the prescriber order, renal function, and current prescribing information.
Missed dose: For intermittent or continuous IV therapy, give the next ordered dose or resume the infusion as soon as practicable once hypocalcemia persists or recurs—contact the prescriber if the patient remains symptomatic or ionized calcium stays below target. Not specified in the reviewed prescribing information for oral missed-dose rules (this product is IV only).
Before you give it — Safety check
Pretreatment checks
- Review indication and most recent ionized (preferred) or corrected total calcium; compare to prescriber target and hold parameters
- Assess IV access—patent, proximal, secure line; confirm ceftriaxone is not running on the same line or Y-site (contraindicated in neonates ≤28 days; sequential administration with line flush in older patients)
- Screen for digoxin or other cardiac glycosides, hypercalcemia risk drugs (thiazides, vitamin D, teriparatide), and calcium channel blockers; obtain baseline ECG when arrhythmia risk is elevated
Contraindications
- Hypercalcemia
- Neonates (28 days of age or younger) receiving ceftriaxone—concomitant IV calcium and ceftriaxone is contraindicated
- Known hypersensitivity to the product (not specified beyond standard precautions in the reviewed prescribing information)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Cardiac glycosides (e.g., digoxin) | Hypercalcemia increases digoxin toxicity; synergistic arrhythmias when calcium and glycosides are given together | Avoid calcium if possible; if required, give slowly in small amounts with continuous ECG monitoring and notify prescriber/pharmacist |
| Ceftriaxone (IV) | Ceftriaxone–calcium precipitates can form emboli; fatal neonatal lung/kidney precipitates reported when given simultaneously | Never co-infuse; in patients >28 days, sequential administration only with thorough line flush between infusions; no Y-site co-administration at any age |
| Fluids with phosphate or bicarbonate; minocycline IV | Physical incompatibility—precipitation; minocycline inactivated by calcium | Use separate lines; flush between agents; consult pharmacy for compatibility questions |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous bolus or continuous infusion only—administer via a secure IV line. Do not administer intramuscularly or subcutaneously per labeling.
- Inspect solution—clear and colorless to slightly yellow; do not use if particulate matter, discoloration, or precipitate is present (warm vial per label if manufacturer precipitate noted)
- Dilute before administration: bolus in D5W or normal saline to 10–50 mg/mL; continuous infusion to 5.8–10 mg/mL; use diluted solution immediately
- Infuse bolus slowly—do not exceed 200 mg/min in adults or 100 mg/min in pediatric patients; monitor vitals and ECG during and after the dose—use an infusion pump when rate control is critical
Extravasation or even local trauma can cause calcinosis cutis, tissue necrosis, ulceration, and infection—discontinue infusion at that site immediately if swelling, pain, induration, or blanching occurs. Rapid injection may cause hypotension, bradycardia, arrhythmias, syncope, or cardiac arrest. Do not mix with ceftriaxone, phosphate, bicarbonate, or minocycline in the same line.
Expected therapeutic response
- Rising ionized calcium on repeat labs within 4–6 hours (intermittent dosing) or 1–4 hours (continuous infusion) per label
- Decreased neuromuscular irritability—relief of perioral numbness, tingling, muscle cramps, carpopedal spasm, or tetany when hypocalcemia was symptomatic
- Stabilization or improvement of hypocalcemia-related ECG changes (for example, prolonged QT) when monitored; no new bradycardia or arrhythmia during infusion
Red flags — Stop and act
Treat these as medication emergencies—not “wait for the next lab draw.”
- Pain, swelling, blanching, or induration at the IV site during or after infusion—stop immediately; treat extravasation per institutional policy
- Bradycardia, hypotension, syncope, or new/worsening arrhythmia during or immediately after infusion—stop calcium; obtain ECG; escalate per protocol
- Confusion, weakness, nausea, polyuria, or lethargy after repeated doses—suspect hypercalcemia (overdose); stop infusion and notify prescriber
- Patient on digoxin with new nausea, vision changes, or arrhythmia after calcium—digoxin toxicity aggravated by rising calcium
- Neonate or patient ≤28 days on ceftriaxone—do not administer calcium on the same line; verify sequential schedule with pharmacy
Adverse effects
| Adverse effect | Notes | Nursing response |
|---|---|---|
| Local soft tissue inflammation / necrosis | Related to extravasation; calcinosis can occur with or without visible extravasation per label | Stop infusion at site; extravasation protocol; prescriber notification |
| Calcinosis cutis | Papules, plaques, nodules at infusion area | Discontinue IV at affected site; wound care referral per policy |
| Hypotension, bradycardia, arrhythmias | Associated with rapid IV administration | Stop infusion; ECG; hemodynamic monitoring; escalation |
| Syncope / cardiac arrest | Life-threatening; rate-related per label | Emergency response; stop calcium |
| Hypercalcemia | Overdose or excessive replacement; confusion, weakness, diuresis when total calcium ≥12 mg/dL | Stop calcium; repeat labs; supportive care |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdosage of Calcium Gluconate Injection may result in hypercalcemia. Neurologic symptoms include depression, weakness, fatigue, and confusion at lower levels; hallucinations, disorientation, hypotonicity, seizures, and coma at severe levels. Renal effects include diminished urine concentrating ability and diuresis when total serum calcium is ≥12 mg/dL per prescribing information.
Antidote
No specific antidote is listed in the reviewed prescribing information; management is supportive—immediately discontinue calcium, restore intravascular volume, and promote urinary calcium excretion when clinically appropriate per prescriber and toxicology guidance.
Contact local poison control or medical toxicology services for significant hypercalcemia per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Calcium gluconate vs calcium chloride—different elemental calcium per mL; never substitute vial-for-vial
- Concentration confusion—100 mg/mL calcium gluconate vs pharmacy dilution to 10–50 mg/mL; verify total mg per bag
- Line sharing errors—ceftriaxone and calcium through one line or Y-site (contraindicated in neonates ≤28 days; sequential flush only in older patients)
- Pharmacy bulk package—100 mL vial labeled not for direct infusion; dispense single patient doses only
- No specific look-alike/sound-alike pair beyond calcium salts was identified in the reviewed sources, but independent double-check with pharmacy is standard for IV electrolytes.
High-risk populations
| Population | Considerations |
|---|---|
| Neonates and premature infants | Ceftriaxone–calcium contraindication ≤28 days; immature renal function increases aluminum toxicity risk from parenteral aluminum in the product (up to 512 mcg/L per label) |
| Renal impairment | Start at the lowest recommended dose; monitor serum calcium every 4 hours; impaired kidney function increases hypercalcemia and aluminum accumulation risk |
| Patients receiving digoxin or with cardiac disease | Arrhythmia and digoxin toxicity risk—ECG monitoring mandatory if calcium must be given; give slowly in small aliquots |
| Pregnancy | Limited human data with Calcium Gluconate Injection in pregnancy. Maternal hypocalcemia increases obstetric risk; untreated hypocalcemia can cause fetal/neonatal complications. Treat maternal hypocalcemia when clinically indicated after prescriber risk–benefit review—insufficient data to rule out drug-associated developmental risk. |
| Lactation | Calcium is a normal component of human milk. It is unknown whether IV calcium gluconate alters milk calcium concentration or affects the breastfed infant. Weigh maternal clinical need against potential infant exposure per prescriber plan. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum calcium and electrolytes per label: q4–6h during intermittent infusions; q1–4h during continuous infusion; more often if renal impairment or symptoms change
- Continuous or serial ECG when bolus rate is rapid, digoxin is present, or patient had pre-existing arrhythmia or QT prolongation
- IV site assessments every 15–30 minutes during infusion for erythema, swelling, pain, or leakage; neurologic symptoms (tingling, tetany, seizures)
Document
- Indication, pre-dose ionized/total calcium, diluent and final concentration, total mg calcium gluconate, infusion rate (mg/min), line location, and who verified ceftriaxone line separation
- Patient response: symptom change, repeat calcium, ECG findings, and any infusion pause or extravasation intervention
- Teaching provided on reporting mouth tingling, muscle cramps, chest palpitations, or IV site discomfort immediately
Patient teaching
- “You may feel warmth during the infusion. Tell us right away if the IV site hurts, swells, or feels tight, or if you develop muscle cramps, numbness around the mouth, chest fluttering, dizziness, or confusion.”
- Explain why staff monitor the heart rhythm and repeat blood tests—calcium must stay in a narrow safe range
- If alert and appropriate, teach that oral calcium and vitamin D may follow IV replacement—do not double-dose home supplements without prescriber guidance
- Breastfeeding patients: discuss that IV replacement is for acute correction; follow prescriber advice about continuing to breastfeed
- Report worsening nausea, excessive urination, severe fatigue, or confusion after treatment—possible hypercalcemia
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Ionized or total calcium at or above prescriber upper limit, or documented hypercalcemia
- Neonate ≤28 days receiving ceftriaxone, or any plan to co-infuse ceftriaxone with calcium on the same line/Y-site
- IV site pain, swelling, extravasation suspicion, or non-patent line—do not restart through the same cannula
- New bradycardia, symptomatic hypotension, or unstable arrhythmia during prior dose until prescriber/ECG review
- Order lacks dilution, rate, or mg dose; pharmacy has not verified compatibility with concurrent IV medications
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Elemental calcium math | Each mL = 9.3 mg elemental calcium; 1 g vial ≈ 93 mg elemental—verify pharmacy conversion when orders state mEq |
| Rate cap | 200 mg/min adults; 100 mg/min pediatrics—program pump in mg/h only after confirming mg/min limit |
| Line choice | Prefer large proximal vein; avoid hand/wrist sites when alternatives exist |
| Ceftriaxone spacing | Flush entire line volume between agents; document time gap when both are due |
| Ask pharmacy when | Calcium chloride vs gluconate confusion, compatibility questions, or pharmacy bulk package dosing |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
After admission or transfer, complete medication reconciliation—calcium gluconate errors cluster around rate violations, calcium chloride mix-ups, ceftriaxone line conflicts, and extravasation on hand or antecubital lines. Treat every dose as a monitored IV procedure—not a routine IV push.
1. Check-before-you-give protocol
- Right patient, drug (calcium gluconate—not chloride), dose in mg, dilution, route (IV), and rate within 200 mg/min (adults) or 100 mg/min (pediatrics)
- Ceftriaxone and calcium never on shared line; digoxin and ECG plan documented when applicable
- Large-bore, proximal, well-flushed IV site with extravasation kit awareness; second nurse verify on pump rate when institution requires
- Most recent calcium and magnesium available—severe hypomagnesemia can resist correction until magnesium is replaced
2. High-alert and safety badge
Not on standard high-alert lists — IV extravasation and rate risk require electrolyte-concentrate vigilanceISMP high-alert lists vary by institution; many hospitals treat IV calcium as a restricted or independent-double-check electrolyte. Follow local policy even when the drug is not nationally classified as high-alert.
3. Clinical workflow: hold and question rules
- If the MAR says “IV push undiluted” or lacks a mg/min rate, hold and request pharmacy clarification before administration
- If calcium chloride appears on the order but the vial reads gluconate (or vice versa), stop and reconcile with pharmacy—elemental calcium content differs
- If repeat calcium rises above target but infusion continues, pause and notify prescriber—evaluate for hypercalcemia per overdose pathway
4. Critical teach-back questions
- “What should you report during the infusion?” (IV site pain or swelling, mouth tingling, muscle cramps, palpitations, dizziness, or confusion.)
- “Why is the nurse watching your heart monitor?” (Fast calcium shifts can slow the heart or trigger arrhythmias—especially if you take digoxin.)
5. Care coordination
Prescriber / endocrine or surgical team: Clarify target ionized calcium, transition to oral calcium/vitamin D, and duration of IV therapy—long-term safety not established per label
Pharmacist: Verify ceftriaxone timing, compatibility, dilution, pump programming, and calcium chloride vs gluconate selection
🧠 Quick mental checklist
- Is ionized calcium low enough to treat—and not already high?
- Is ceftriaxone off this line (and patient age >28 days if both are ordered)?
- Did I dilute and cap the rate with ECG monitoring when required?
- Is the patient on digoxin or at high arrhythmia risk?
- Can I see the IV site for the entire infusion?
Calcium Gluconate NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for calcium gluconate using a tabbed hypocalcemia case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, post-infusion trend interpretation, matrix urgency, clinical judgment, and documentation cloze—recognise extravasation and rate cues → analyse calcium and digoxin risk → prioritise line and ECG safety → act → evaluate outcomes with repeat ionized calcium and rhythm checks.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Calcium gluconate 2 g IV STAT — dilute in 100 mL NS; infuse over 10–15 min per pharmacy label (200 mg/min max)
- Digoxin 0.125 mg PO daily
- Ceftriaxone 1 g IV q24h — due in 4 hours (different line ordered)
- Calcitriol 0.25 mcg PO daily
- Ionized calcium now 0.78 mmol/L (low) — was 0.92 mmol/L six hours ago
- Total calcium 7.4 mg/dL; albumin 3.1 g/dL
- Magnesium 1.4 mg/dL (low-normal)
- Potassium 4.2 mEq/L; creatinine 1.6 mg/dL (baseline for CKD stage 3)
- HR 58/min, BP 102/64 mmHg, RR 16, SpO2 97% on room air
- Patient reports perioral tingling and hand cramping
- Telemetry: sinus rhythm with QTc 492 ms (prolonged vs admission)
- Right forearm 20-gauge IV — site without erythema at start of shift
- Post–parathyroidectomy day 1 — watch for hungry bone syndrome
- Prior shift: patient refused oral calcium citrate; hypocalcemia symptoms worsened overnight
- Pharmacy sticker: “Do not co-infuse with ceftriaxone — flush line between agents”
- Educate on reporting mouth tingling, spasms, or palpitations during infusion
Answer key & rationale
Frequently asked questions
Why must calcium gluconate be diluted and infused slowly?
FDA labeling states rapid IV injection may cause vasodilation, hypotension, bradycardia, arrhythmias, syncope, or cardiac arrest. Bolus doses should be diluted in D5W or normal saline and infused no faster than 200 mg/min in adults or 100 mg/min in pediatric patients, with ECG monitoring recommended during administration.
When should a nurse hold calcium gluconate?
Hold for hypercalcemia, extravasation or a non-patent IV site, neonates ≤28 days receiving ceftriaxone (contraindicated combination), simultaneous ceftriaxone on the same line or Y-site at any age, new bradycardia or unstable arrhythmia during prior dose, or unclear orders lacking dilution and rate. Follow prescriber and pharmacy clarification before giving.
What is the difference between calcium gluconate and calcium chloride?
Both treat hypocalcemia IV, but each mL of calcium gluconate 10% contains 9.3 mg (0.465 mEq) elemental calcium, whereas calcium chloride concentrates more elemental calcium per mL. They are not interchangeable milliliter for milliliter. Calcium gluconate is generally preferred when extravasation risk is high because tissue injury can still occur but chloride extravasation is often more severe. Always verify the vial label and pharmacy calculation.
How often should serum calcium be monitored during IV therapy?
Prescribing information recommends measuring serum calcium every 4 to 6 hours during intermittent infusions and every 1 to 4 hours during continuous infusion. Renal impairment requires starting at the lowest dose range and monitoring calcium every 4 hours.
What happens if too much calcium gluconate is given?
Overdosage may cause hypercalcemia. Symptoms can include weakness, confusion, hallucinations, hypotonicity, seizures, coma, and diuresis when total serum calcium is ≥12 mg/dL. Management is to stop calcium immediately, provide supportive care, and promote calcium excretion when appropriate. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Calcium Gluconate Injection, USP — prescribing information (Fresenius Kabi USA, LLC; NDA 208418). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b77c3d2-992d-4261-8421-9cfd07328fbf
-
Spiegel DM, Marcus K. Hypocalcemia. StatPearls. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK430912/
-
U.S. Food and Drug Administration. Drug Safety Communication: Updated information on concomitant use of ceftriaxone and calcium-containing products.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-contraindication-ceftriaxone-rocephin-and-calcium
-
Shkembi B, O’Sullivan SM. Calcium Gluconate. StatPearls. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK557463/
-
U.S. National Library of Medicine. Calcium Gluconate Injection — Highlights of Prescribing Information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8b77c3d2-992d-4261-8421-9cfd07328fbf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.